The Governing Council of the University of Toronto

Bausch + Lomb launches the second annual Faces of Glaucoma campaign in January, partnering with the Glaucoma Research Foundation to raise awareness, share patient stories, and provide educational resources. They will match donations up to $20,000. The campaign emphasizes the importance of early detection and management of glaucoma. Bausch + Lomb also acquired Elios Vision, introducing the ELIOS procedure, a minimally invasive glaucoma surgery, to enhance their glaucoma treatment offerings.

Human cells are complex, with new technologies revealing thousands of types. Generative AI, inspired by models like ChatGPT, is being developed to simulate cells, potentially revolutionizing medicine by predicting drug effects and understanding biological processes. Despite challenges, including the need for vast data and the complexity of combining models, scientists aim to create virtual cells and organisms, advancing research and treatment possibilities.

A study in Nature Genetics shows ZIC1 gene mutations drive medulloblastoma, a common childhood brain tumor, through distinct mechanisms in G4 and SHH types. Findings suggest context-dependent treatment strategies, targeting either inhibition or restoration of ZIC1 function.

The alfapump system effectively controls ascites in cirrhosis patients, improving quality of life and reducing therapeutic paracentesis needs. It offers 10 additional good health days monthly, with safety events consistent for this patient population. US FDA approved in December 2024, with a commercial launch planned for H2 2025.

The alfapump® system effectively controls ascites in liver cirrhosis patients, improving quality of life and reducing therapeutic paracentesis needs. It offers 10 additional good health days monthly, with safety consistent for this patient population. US FDA approved in December 2024, with a commercial launch planned for H2 2025.

The alfapump® system effectively controls ascites in liver cirrhosis patients, reducing the need for therapeutic paracentesis and improving quality of life by adding 10 good health days per month. It received US FDA approval in December 2024, with a commercial launch planned for H2 2025. The POSEIDON study demonstrated its efficacy and safety, showing higher overall survival rates compared to standard care.

Regeneron's pozelimab and cemdisiran combo shows promise in PNH treatment, outperforming AstraZeneca's Ultomiris in LDH control. With 96% achieving adequate LDH control vs. Ultomiris's 80%, and 93% normalizing LDH levels vs. 65%, the subcutaneous treatment could transform PNH therapy. Regeneron and Alnylam are exploring its use in other diseases.

Pozelimab combined with cemdisiran shows superior control of intravascular hemolysis in PNH patients compared to Ultomiris, with 96% achieving target LDH levels versus 80%. The combination offers potential for self-administration with infrequent dosing, indicating a promising treatment for PNH and other complement-mediated diseases.

Pozelimab combined with cemdisiran shows superior control of intravascular hemolysis in PNH patients compared to Ultomiris, with lower LDH levels and potential for self-administration. Ongoing Phase 3 trials and extensions aim to confirm its efficacy and safety, offering hope for better PNH treatment.

Hemostemix Inc. applies to up-list on the OTCQB Venture Market to enhance liquidity across USA, Europe, and Canada. Its ACP-01 therapy shows significant efficacy, with 83% of Phase II trial patients experiencing ulcer healing and ischemic rest pain resolution. Cardiac function improved up to 47.1% in cardiomyopathy patients. The therapy targets a vast market, with 236 million suffering from peripheral arterial disease.